Background {#Sec1}
==========

Malnutrition can be described as a nutrient intake lower than the nutritional needs of the individual (Fouque et al. [@CR8]). The presence of malnutrition is reported in approximately 20 - 50% of the haemodialysis population (Kopple [@CR14]; Marcen et al. [@CR17]; Aparicio et al. [@CR2]) and is a factor in protein and energy wasting (PEW). PEW can be defined as \''...a depletion of protein mass and / or energy fuel supplies....." (Fouque et al. [@CR8]) and has many associated consequences including increased mortality and morbidity, decreased quality of life (QOL) and increased risk of hospitalisation. There are many causes of malnutrition in the haemodialysis population including a decreased appetite and subsequent oral intake due to uraemic toxins (Carrero et al. [@CR5]), protein losses on dialysis (Wolfson et al. [@CR22]) and the catabolic effect of dialysis (Kalantar-Zadeh et al. [@CR12]; Ikizler [@CR10]).

Interventions to improve nutritional status through an increase in nutrient intake include the encouragement of food fortification techniques through dietary counselling with a renal dietitian (Akpele and Bailey [@CR1]; Fouque et al. [@CR7]), the use of oral nutritional supplements (ONS) and enteral or parenteral nutrition (Stratton et al. [@CR21]) all of which have been shown to improve markers of nutritional status in some way.

The measurement of nutritional status is particularly difficult due to its complex causes and multiple variables. Nutritional status cannot be measured with a single parameter but should be classified using a variety of reproducible measures that predict outcome (Fouque et al. [@CR7]). In view of this, previous studies measuring the impact of ONS in haemodialysis patients have used a variety of measures including albumin (Sharma et al. [@CR20]; Kalantar-Zadeh et al. [@CR13]) subjective global assessment (Fouque et al. [@CR9]; Calegari et al. [@CR4]), QOL (Scott et al. [@CR18]; Calegari et al. [@CR4]) and anthropometric measures such as tricep skinfold thickness, mid arm muscle circumference (Beutler et al. [@CR3]) and handgrip strength (Leal et al. [@CR15]).

Rationale for pilot study {#Sec2}
-------------------------

Many of the previous studies aiming to improve nutritional status in this population recommend the need for further research as the most appropriate type of nutritional support, the timing of ingestion and which nutritional markers should be used to best assess their efficacy are still not clear. Larger scale trials have not been conducted to date and there are a number of parameters which need investigation before a definitive protocol can be developed.

Aim and objectives {#Sec3}
------------------

The aim of this study is to conduct a randomised controlled external pilot trial to assess the effect of an intradialytic oral nutritional supplement on nutritional status.

The primary objectives are to: demonstrate the feasibility, practicality, safety and acceptability of a nutritional intervention study protocol, including the willingness to be randomised to treatment, in the haemodialysis population; To determine recruitment, withdrawal and drop-out rates and use these to estimate such parameters over the longer term; To identify any preference for types of nutritional supplement and adherence to the intervention schedule; To determine the completion rates of the study questionnaires; To assess QOL, exploring whether the frequency and length of the QOL assessment is acceptable to this patient population.

Secondary outcomes include clinical measures of weight, handgrip strength, biochemistry and QOL with the confounding factor of dietary intake also being assessed. These clinical parameters will be utilised to estimate the effect size and variability of outcome measures to inform the sample size calculation for a full trial.

Methods/design {#Sec4}
==============

NOURISH is a two-arm parallel group randomised controlled external pilot trial of ONS versus standard care in haemodialysis patients. The trial will be conducted in a single centre with an intervention and control group. Both groups will receive standard care, but the intervention group will additionally take an ONS each dialysis session from a choice of prescribable drink or pudding style supplements in various flavours.

Participant selection and setting {#Sec5}
---------------------------------

Adult renal haemodialysis patients will be recruited from an NHS hospital dialysis unit in Sheffield, UK. Patients will be identified, screened for eligibility and asked if they agree to participate by a renal dietitian when they attend one of their thrice weekly dialysis sessions. Inclusion and exclusion criteria are listed in Table [1](#Tab1){ref-type="table"}. We will collect basic unidentifiable details on all eligible patients to allow completion of a CONSORT flow diagram (Figure [1](#Fig1){ref-type="fig"}).Table 1**Inclusion and exclusion criteria for study participants**Inclusion criteriaExclusion criteria• Adult haemodialysis patients (≥18 years of age)• Amputees• Received dialysis for at least 6 months prior to study screening• Significant oedema• Receive haemodialysis at least 3 times per week at the main haemodialysis unit (not satellite centre)• Non fluent English• Body Mass Index ≤22 kg/m2• Receiving nutritional supplementation prior to study commencing or within 1 month of commencement in the study• Participants with an allergy to any ingredients in the nutritional supplements• Persistent hyperkalaemia or hyperphosphataemia (defined as the last 3 months).Figure 1**CONSORT flowchart of trial.**

The inclusion criteria include a BMI ≤22 kg/m^2^ this was chosen as a BMI at the lower end of the normal range (18.5 -25 kg/m^2^) has been indicated as detrimental to haemodialysis patients (Fleischmann et al. [@CR6]; Leavey et al. [@CR16]).

Amputees and those with significant oedema or an unstable dry weight will be excluded from this pilot trial due to the inaccuracy of assessing the height and thus the BMI of amputees and the oedema / fluid overload of patients falsely elevating their weight and consequently their BMI.

Sample size {#Sec6}
-----------

To the authors knowledge no large randomised trials investigating the efficacy of intradialytic ONS have been conducted to date. Sufficient data on estimates of the standard deviation of the proposed outcome measures in this population are not available to enable a sample size to be calculated. This pilot trial is designed to collect this data to inform the sample size for a larger definitive trial in the future.

In order to collect sufficient data to inform a future sample size calculation we need 12 evaluable participants per arm, a total of 24 (Julious [@CR11]). The aim will therefore be to recruit 30 patients to take into account any withdrawal.

Trial treatment {#Sec7}
---------------

All participants will continue to attend their usual haemodialysis sessions at a frequency of 3 times a week and may receive information from a renal dietitian as per standard treatment, regardless of group allocation. The intervention group will in addition, be requested to ingest 1 ONS per dialysis session over a 2 month intervention period. Participants will receive a choice of ONS; a drink or two styles of pudding in various flavours will be available, with the aim to improve adherence through choice. The supplements vary in their nutritional composition but will all provide between 200 and 300 Kcal and 10.5 -- 12 g protein per dialysis session. The differences in composition are small but the specific supplements have been chosen due to the low fluid volume they provide, an important factor in an often fluid restricted population.

Participants will complete a short questionnaire each dialysis session regarding their general wellbeing, intradialytic oral intake and for those in the intervention arm information about the amount of supplement taken and any preferences for type of ONS.

Handgrip strength, measured by dynamometry, QOL measured using SF-12V2 ([@CR19]), Weight in kg, biochemical markers, and dietary intake will be measured at baseline, month 1 and at the end of the intervention (month 2).

These clinical endpoints will help determine the most appropriate outcome measures and timing of data collection points for a larger randomised controlled trial and inform the sample size calculation.

Primary outcomes {#Sec8}
----------------

This trial is designed to assess feasibility outcomes. The recruitment rate, calculated as the proportion of those screened who are subsequently consented into the trial within the specified recruitment period will be assessed. The practicalities of recruitment and the study protocol including barriers to recruitment, adherence to the intervention (including palatability and preference for types of ONS), withdrawal and loss to follow-up, the feasibility, acceptability and appropriateness of data collection methods and data completion rates will also be recorded.

Analysis {#Sec9}
--------

Primary analysis will be intention to treat but per protocol analysis will also be performed if relevant. Logs of patients screened and approached to participate, will be kept along with the time taken to approach, request consent and to complete each assessment to inform possible recruitment rates for future larger studies.

Data from all randomised patients will be analysed including those that may have withdrawn from the treatment arm but allow their data to be used for analysis up to the point of withdrawal. Descriptive statistics will be used to analyse the baseline characteristics of the recruited participants. Means, confidence intervals, minimum and maximum along with standard deviations will be reported for the secondary outcome measures of handgrip strength, dietary intake, QOL, biochemistry and weight.

Ethical approval and research governance {#Sec10}
----------------------------------------

The trial has approval from the Leeds East National Research Ethics Service Committee, reference number 13/YH/0092. The trial will be conducted in compliance with the protocol, GCP and regulatory requirements. The trial is sponsored by the local NHS Trust (Sheffield Teaching Hospitals NHS Foundation Trust) and will be subject to the research and development department management and monitoring procedures.

Discussion {#Sec11}
==========

Randomisation and blinding {#Sec12}
--------------------------

Once eligibility has been confirmed and consent acquired the participants will be randomly allocated to treatment group via a bespoke web-based randomisation system provided by a University of Sheffield subsidiary company, EpiGenesys. The randomisation system will only reveal the allocated treatment (ONS or standard care) after participants details have been recorded and the participant entered into the trial. To reduce the risk of random imbalances in the number allocated to each arm of the trial, randomisation will be stratified by gender and age of participant. Due to the small sample size of this pilot study it may be difficult to stratify the sample population but we think it is important to test the randomisation system fully prior to a larger trial so stratification will be incorporated.

Due to the nature of the intervention trial participants and staff will not be blinded to treatment allocation. We will consider whether it would be better to include a placebo ONS in the definitive trial, but one of the aims of the pilot is to assess palatability of different styles of ONS so it is not feasible to blind in the pilot. The outcome assessor performing the handgrip strength and dietary assessment is also not blinded in the pilot but this will be addressed for the definitive trial.

Any side effects or adverse events reported by the patient, observed by clinical staff or determined during case note review will be recorded. There is a small risk of gastrointestinal disturbances and hypotension following ingestion of the ONS. There is a small risk attached to the conduction of the handgrip assessment, it could cause bleeding from the arteriovenous fistula, and so will be conducted on the arm without vascular access, this will also be documented to aid analysis.

Trial status {#Sec13}
------------

Recruitment to the trial is underway at the time of manuscript submission. Recruitment is due to take place between May and June 2013. The collection of participant data will conclude in August 2013, and analysis is planned to be completed by December 2013.
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